Business Context and Reporting Period
This Form 8-K is filed by IDEAYA Biosciences, Inc. (IDYA) on December 9, 2025, reporting the termination of a material definitive agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited ("GSK").
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. However, management states that the termination does not change the company's expectation of a cash runway extending into 2030.
Material Changes
- Agreement Termination: GSK delivered formal written notice on December 9, 2025, electing to terminate the Collaboration, Option and License Agreement dated June 15, 2020.
- Effective Date: The termination will become effective 90 days after the notice, on March 9, 2026.
- Program Transfer: During the 90-day transition period, GSK will transfer the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA Biosciences.
Outlook, Risks, and Management Commentary
Management plans to evaluate strategic options for the IDE275 and IDE705 programs in 2026 following the transfer. The company reiterates that its cash runway guidance remains unchanged. The filing includes standard forward-looking statement disclaimers regarding risks inherent in drug development, regulatory approvals, manufacturing challenges, and the sufficiency of existing cash to fund operations.
Investor Verification Checklist
- Confirm the specific financial impact of the program transfer on future operating expenses.
- Review the detailed terms of the Collaboration, Option and License Agreement (Exhibit 10.3) for any remaining financial obligations or liabilities.
- Verify the current status and development stage of the IDE275 and IDE705 clinical programs.
- Assess the company's updated capital allocation strategy for the two programs in 2026.